MVIC And Upperton Pharma Solutions Announce Strategic Collaboration

Integrated development-to-clinical manufacturing pathway strengthens the customer offering from discovery through clinical trial supply.

Lund, Sweden And Nottingham, United Kingdom - MVIC (Medicon Valley Inhalation Consortium) and Upperton Pharma Solutions today announced a strategic collaboration designed to provide pharmaceutical and biotech companies with a seamless, end-to-end solution spanning early discovery, formulation development, preclinical support, and clinical trial manufacturing.

The collaboration brings together MVIC's extensive expertise in inhalation and nasal drug development with Upperton's advanced formulation, spray drying, sterile manufacturing, scale-up, and GMP clinical manufacturing capabilities. Together, the two organizations will offer customers a streamlined pathway from concept through clinical trial supply, reducing development complexity and accelerating project timelines.

Through this collaboration, customers will benefit from a coordinated one-stop-shop approach, with integrated project management, scientific oversight, and development expertise across the entire value chain. The partnership is expected to be particularly valuable for companies developing inhaled, nasal, and other complex drug products requiring specialized formulation and manufacturing expertise.

“Our ambition is to simplify drug development for our customers by offering a seamless route from discovery and early development through clinical manufacturing. By combining MVIC’s scientific and project management expertise with Upperton’s world-class manufacturing and formulation capabilities, we can provide a highly efficient and coordinated development pathway that helps bring innovative medicines to patients faster.”

Mats Håkansson, CEO of MVIC

Upperton Pharma Solutions will contribute its expertise in formulation optimization, spray drying, sterile development and manufacture, process scale-up, GMP production of clinical trial materials, packaging and labeling, quality systems support, and distribution for clinical studies. These capabilities complement MVIC's strengths in formulation design, device selection and optimization, preclinical testing, toxicology strategy, regulatory support, and project leadership.

“We are delighted to collaborate with MVIC to create a more integrated offering for pharmaceutical innovators. Together, we can help clients move more efficiently from innovative concepts to clinical evaluation by combining scientific excellence with robust manufacturing expertise.”

Nikki Whitfield, CEO of Upperton

The collaboration reflects a shared commitment to supporting pharmaceutical and biotech innovators with specialist expertise, flexible project execution, and a customer-centric approach. By working together from the earliest stages of development, MVIC and Upperton aim to improve knowledge transfer, reduce development risk, and enable a smoother transition into clinical manufacturing activities.

About MVIC

MVIC (Medicon Valley Inhalation Consortium) is a leading drug development organization specializing in inhalation and nasal drug delivery. Through its network of experts and partner organizations, MVIC supports pharmaceutical and biotechnology companies from discovery through clinical development, providing expertise in formulation development, device optimization, regulatory support, toxicology, and project management.

About Upperton Pharma Solutions

Upperton Pharma Solutions has over 25 years’ experience of delivering science-led, high quality, innovative early drug development solutions to pharmaceutical and biotechnology clients worldwide. 

Based in Nottingham, UK, Upperton has formulation and analytical development laboratories, alongside a fully equipped GMP manufacturing and Quality Control testing capability and is licensed by the MHRA to manufacture materials for clinical trial supplies. In addition to supporting conventional oral solid dosage form development, Upperton has a strong history in spray drying which is applied to address both the challenges with poorly soluble molecules and as a particle engineering technology for targeted deposition for pulmonary and nasal drug products.

The company employs over 125 highly skilled personnel and has its headquarters in Nottingham, UK.